SCHEMBL9911348

SCHEMBL9911348

CC(C)NCCc1ccc(O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.64
ADRB2 P07550 4/20 0.64
HIF1A Q16665 3/20 0.64
SLC6A2 P23975 3/20 0.64
SLC6A4 P31645 3/20 0.64
OPRM1 P35372 3/20 0.64
OPRK1 P41145 3/20 0.64
CYP2D6 P10635 2/20 0.64
ADRB1 P08588 2/20 0.64
ADRA1A P35348 2/20 0.64
SLC6A3 Q01959 2/20 0.64
GALR3 O60755 1/20 0.64
SIGMAR1 Q99720 4/20 0.62
TMEM97 Q5BJF2 2/20 0.62
ADRB3 P13945 1/20 0.62
KDM4E B2RXH2 3/20 0.57
MAPK1 P28482 2/20 0.57
CA2 P00918 2/20 0.57
SLC22A1 O15245 1/20 0.57
CA12 O43570 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10816522 0.88 SIGMAR1 (0.64) LMNAADRB2HIF1ASLC6A2SLC6A4
SCHEMBL10814123 0.86 SIGMAR1 (0.58) LMNAADRB2HIF1ASLC6A2SLC6A4
SCHEMBL23695828 0.81 SIGMAR1 (0.49) LMNAADRB2HIF1ASLC6A2SLC6A4
SCHEMBL13996937 0.81 L3MBTL1 (0.47) LMNAADRB2HIF1ASLC6A2SLC6A4
SCHEMBL10087662 0.81 ALDH1A1 (0.47) LMNAADRB2HIF1ASLC6A2SLC6A4
Bromide SCHEMBL11285071 0.81 SIGMAR1 (0.48) LMNAADRB2HIF1ASLC6A2SLC6A4
SCHEMBL13532079 0.79 TAAR1 (0.61) LMNAADRB2SLC6A2CYP2D6SLC6A3
SCHEMBL20024425 0.79 SIGMAR1 (0.53) LMNAADRB2HIF1ASLC6A2SLC6A4
SCHEMBL255039 0.79 GFER (0.52) LMNAADRB2HIF1ASLC6A2SLC6A4
SCHEMBL15031576 0.79 LMNA (0.50) LMNAADRB2HIF1ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-20230041761-A1 SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF NORTHWESTERN UNIVERSITY 2023-02-09 US disclosed
US-20210292285-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS NUVATION BIO INC (US) 2021-09-23 US disclosed
US-11028058-B2 Heterocyclic compounds as adenosine antagonists NUVATION BIO INC. (US) 2021-06-08 US disclosed
US-20200231570-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2020-07-23 US disclosed
US-20190023666-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-01-24 US disclosed
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-07-20 US disclosed
CN-102898317-B Organic amino compounds serving as immunopotentiators, metabolic enhancers or roborants and preparation method and use thereof UNIV SICHUAN AGRICULTURE 2015-04-22 CN disclosed
CN-102898317-A Organic amino compounds serving as immunopotentiators, metabolic enhancers or roborants and preparation method and use thereof UNIV SICHUAN AGRICULTURE 2013-01-30 CN disclosed
US-8198458-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-12 US disclosed
WO-2012003478-A2 DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY VENTANA MEDICAL SYSTEMS, INC. (US) 2012-01-05 WO disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20090143370-A1 Non-nucleoside Reverse Transcriptase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 US disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed
EP-0100033-B1 SUBSTITUTED (10H-PHENOTHIAZIN-10-YL)PROPYL-1-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEREAPEUTIC AGENTS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1987-01-14 EP disclosed
US-4471116-A Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines HOFFMANN-LA ROCHE INC. (US) 1984-09-11 US disclosed
EP-0100033-A1 Substituted (10H-phenothiazin-10-yl)propyl-1-piperazine derivatives, process for their preparation and thereapeutic agents containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 LMNA 4865/4885ADRB2 4820/4885HIF1A 2937/4885
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 LMNA 2696/4885ADRB2 4551/4885HIF1A 1744/4885
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME HSPH1, HBZ, PITHD1 LMNA 1023/4885ADRB2 767/4885HIF1A 177/4885
US-20190023666-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS ADORA2A, ADORA3, ADORA1 LMNA 4458/4885ADRB2 133/4885HIF1A 1547/4885
US-11028058-B2 Heterocyclic compounds as adenosine antagonists ADORA2A, ADORA3, ADORA1 LMNA 4458/4885ADRB2 133/4885HIF1A 1547/4885
US-20200231570-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS ADORA2A, ADORA3, ADORA1 LMNA 4458/4885ADRB2 133/4885HIF1A 1547/4885
US-20210292285-A1 HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS ADORA2A, ADORA3, ADORA1 LMNA 4458/4885ADRB2 133/4885HIF1A 1547/4885
US-20230041761-A1 SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF SIGMAR1, TMEM97, OPRM1 LMNA 4760/4885ADRB2 12/4885HIF1A 1798/4885
US-20090143370-A1 Non-nucleoside Reverse Transcriptase Inhibitors RTF1, POLR1A, POLR1E LMNA 2438/4885ADRB2 1536/4885HIF1A 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.